Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia
Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia
复制标题
ADCK1基因的遗传变异预测帕潘立酮棕榈酸酯对中国汉族精神分裂症患者的疗效
DOI：
10.1007/s00702-018-1953-6
复制
发表时间：
2019-01-01
影响因子：
3.3
通讯作者：
Si, Tian-Mei
中科院分区：
文献类型：
--
作者：
Su, Yun-Ai;Bousman, Chad;Si, Tian-Mei
全基因组关联研究结果在欧洲队列中将ADCK1基因变异与帕利培酮疗效联系起来。然而，该基因座在非欧洲人群中的普适性尚不清楚。对159例汉族人精神分裂症患者给予帕利哌酮棕榈酸酯治疗，3个月后评定症状严重程度。对13个ADCK1基因变异的检测发现，两个单核苷酸多态(rs12590199，rs11159291)和一个单倍型(rs2364747-rs12590199)与帕利哌酮棕榈酸酯反应相关。ADCK1的S功能及其与帕利培酮的潜在相互作用有待进一步研究。
Genome-wide association study results have linked ADCK1 genetic variation with paliperidone efficacy in a European cohort. However, the generalizability of this locus to non-European populations is unknown. Han Chinese schizophrenia patients (n = 159) were treated with paliperidone palmitate and symptom severity was assessed over 3 months. Examination of 13 ADCK1 genetic variants revealed two single nucleotide polymorphisms (rs12590199, rs11159291) and one haplotype (rs2364747-rs12590199) associated with paliperidone palmitate response. Future work into ADCK1's function and its potential interaction with paliperidone is warranted.